Dynavax Technologies | DVAX - Trade Creditors


Dynavax Technologies reported $2.7M in Trade Creditors for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 918.45M
Cash and Equivalent USD 99.1M
Cost of Sales USD 14.04M
Current Assets USD 785.71M
Current Liabilities USD 118.23M
Debt USD 260.51M
EBIT USD 10.86M
EBITDA USD -21.59M
Employees 405
EPS Earnings Per Share USD 0.14
Equity Capital and Reserves USD 494.16M
Gross Profit on Sales USD 78.57M
Interest Expense on Debt USD 1.64M
Interest Income USD 7.74M
Loan Capital USD 220.75M
Market Capitalization USD 1.27B
Net Income USD 18.72M
Operating Expenses USD 81.01M
Operating Profit USD 10.86M
Ordinary Share Capital USD 117.23M
PE Price to Earnings USD 47.66
Pre-Tax Profit USD 21.22M
Sales Revenues USD 95.44M
Selling and Administration Expenses USD 41.54M
Stock USD 75.69M
Trade Creditors USD 2.7M
Trade Debtors USD 73.35M

Trade Creditors Change Date
AbbVie USD 2.94B 2.66B Dec/2024
Adma Biologics USD 29.77M 9.55M Jun/2025
Amgen USD 18.03B 15.63B Jun/2025
AstraZeneca USD 23.99B 1.44B Jun/2025
Biogen USD 408.4M 16.9M Jun/2025
BioMarin Pharmaceutical USD 684.25M 390.5M Jun/2025
Bristol-Myers Squibb USD 5.43B 1.42B Jun/2025
Dynavax Technologies USD 2.7M 1.63M Jun/2025
Gilead Sciences USD 582M 155M Jun/2025
Glaxosmithkline GBP 13.65B 10.19B Jun/2025
Merck USD 4.04B 261M Jun/2025
Neurocrine Biosciences USD 104.6M 5.4M Jun/2025
Novartis USD 4.51B 245M Jun/2025
Pfizer USD 5.17B 74M Jun/2025
Regeneron Pharmaceuticals USD 723.9M 18.4M Jun/2025
Roche Holding CHF 4.35B 828M Dec/2024
Sarepta Therapeutics USD 136.7M 19.4M Jun/2025
TG Therapeutics USD 134.02M 92.06M Jun/2025
Vertex Pharmaceuticals USD 3.71B 3.27B Jun/2025